Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CTXR stock hub

Citius Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CTXRis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

17.3M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CTXR

In the news

Latest news · CTXR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E0.3

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-47.9

P25 -105.6P50 -46.5P75 -3.1

ROIC-28.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CTXR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

202

Groups with data

Currency

USD

Showing 202 of 202 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001506251
Company name	Citius Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	17322U207
Employees	23
Employees Change	1%
Employees Change Percent	4.55
Enterprise value	$11.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US17322U3068
Last refreshed	2026-05-10
Market cap	$17.3M
Market cap category	Nano-Cap
Price	$0.64
Price currency	USD
Rev Per Employee	171,483.09x
Sector	Healthcare
Sic	2834
Symbol	CTXR
Website	https://citiuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-206.86%
EV Sales Forward	0.13x
EV/Sales	2.9x
FCF yield	-200.8%
Forward P/E	0.33x
P/B ratio	0.18x
P/S ratio	4.4x
PS Forward	0.2x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	79.99%
Gross Profit	$3.2M
Net Income	$-35.9M
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Pretax Margin	-958.29%
Profit Per Employee	$-1.6M
ROA	-17.68
Roa5y	-19.28
ROCE	-36.14
ROE	-47.85
Roe5y	-37.93
ROIC	-28.08

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-48.88%
Cagr1y	-8.18%
Cagr3y	-72.85%
Cagr5y	-58.86%
EPS Growth Quarters	6
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$140.4M
Cash	$7.7M
Current Assets	$37.9M
Current Liabilities	$38.2M
Debt	$1.8M
Debt Equity	$0.02
Equity	$93.5M
Interest Coverage	-87.24
Liabilities	$46.9M
Long Term Assets	$102.4M
Long Term Liabilities	$8.7M
Net Cash	$5.9M
Net Cash By Market Cap	$33.96
Net Cash Growth	557.92%
Net Debt Equity	$-0.06
Tangible Book Value	$-21.6M
Tangible Book Value Per Share	$-0.97
WACC	10.81

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.99
Inventory Turnover	0.04
Net Working Capital	$-6.8M
Quick ratio	0.31
Working Capital	$-261,987
Working Capital Turnover	$-0.29

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-107.77%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.88%
1Y total return	-8.18%
200-day SMA	1.06
3Y total return	-98%
50-day SMA	0.79
50-day SMA vs 200-day SMA	50under200
5Y total return	-98.82%
All Time High	937.5
All Time High Change	-99.93%
All Time High Date	2016-02-09
All Time Low	0.57
All Time Low Change	12.28%
All Time Low Date	2026-04-29
ATR	0.07
Beta	1.05
Beta1y	3.8
Beta2y	2.25
Ch YTD	-17.63
High	0.66
High52	2.48
High52 Date	2025-07-03
High52ch	-74.19%
Low	0.62
Low52	0.57
Low52 Date	2026-04-29
Low52ch	12.28%
Ma50ch	-19.17%
Premarket Change Percent	-0.2
Premarket Price	$0.65
Premarket Volume	14,394
Price vs 200-day SMA	-39.57%
RSI	39.18
RSI Monthly	34.54
RSI Weekly	38.26
Sharpe ratio	0.5x
Sortino ratio	0.96
Total Return	-107.77%
Tr YTD	-17.63
Tr1m	-18.88%
Tr1w	-8.57%
Tr3m	-15.2%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.32
Earnings Revenue Estimate	9,871,000x
Operating Income	$-36.9M
Operating margin	-936.4
Price target	$6
Price Target Change	$838

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26,613,998%
Float Percent	98.18%
Net Borrowing	1,000,000
Shares Insiders	1.82%
Shares Institutions	6.26%
Shares Out	27,106,884
Shares Qo Q	24.97%
Shares Yo Y	107.77%
Short Float	15.05%
Short Ratio	8.95
Short Shares	14.77

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-47.6M
Average Volume	930,648.3x
Bv Per Share	3.57
Ch10y	-99.88
Ch1m	-18.88
Ch1w	-8.57
Ch1y	-8.18
Ch3m	-15.2
Ch3y	-98
Ch5y	-98.82
Ch6m	-48.8
Change	-2.16%
Change From Open	-3.03
Close	0.65
Days Gap	0.9
Depreciation Amortization	574,512
Dollar Volume	553,680.6
Earnings Date	2026-05-12
Earnings Time	amc
EBIT	$-36.9M
EBITDA	$-36.4M
EPS	$-2.46
F Score	2
FCF	$-34.8M
FCF EV Yield	-304.07x
FCF Per Share	$-1.29
Financing CF	51,607,022
Fiscal Year End	September
Founded	2,007
Goodwill	9,346,796
Income Tax	$1.1M
Investing CF	-10,150,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-02-13
Last Report Date	2025-12-31
Last Split Date	2024-11-26
Last Split Type	Reverse
Last10k Filing Date	2025-12-23
Ma150	0.98
Ma150ch	-34.95%
Ma20	0.76
Ma20ch	-15.68%
Net CF	6,621,314
Next Earnings Date	2026-05-22
Open	0.66
Optionable	Yes
Position In Range	48.9
Post Close	0.64
Postmarket Change Percent	2.11
Postmarket Price	$0.65
Ppne	835,177
Pre Close	0.65
Price Date	2026-05-08
Relative Volume	0.93x
Revenue	3,944,111x
SBC By Revenue	324.39x
Share Based Comp	12,794,401
Tax By Revenue	26.8x
Tr6m	-48.8%
Us State	New Jersey
Volume	865,126
Z Score	-3.08

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CTXR pay a dividend?

Capital-return profile for this ticker.

Performance

CTXR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CTXR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+6.3%

Float: +98.2% of shares outstanding

Insider ownership

+1.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CTXR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

39.2

Neutral momentum band

Price vs 200-day MA

-39.6%

50/200-day relationship not available

Beta (5Y)

1.05

Moves roughly with the market

Sharpe ratio

0.50

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CTXR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CTXR stock rating?

Citius Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CTXR analysis?

The full report lives at /stocks/CTXR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CTXR?

The latest report frames CTXR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CTXR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.